News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 181–216
- Matches
- 2404
- Sources here
- 16
- Companies here
- 28
Active search
2404 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
BFAM vs. ULS: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Business - Services sector might want to consider either Bright Horizons Family Solutions (BFAM) or UL Solutions Inc. (ULS). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer …
What Abbott Laboratories (ABT)'s AI-Powered Google Health Partnership Means For Shareholders
Abbott Laboratories has partnered with Google Health to integrate glucose insights from its Lingo biowearable into the Google Health app, using AI for personalized metabolic health coaching and unified wellness data. This collaboration includes a large-scale metabolic health study, potentially supporting Abbott's diabetes franchise …
Charles River Laboratories stock hits 52-week high at $285.13 By Investing.com
Charles River Laboratories International Inc. (CRL) stock has reached a 52-week high of $285.13, reflecting an 83.28% increase over the past year and a 41.4% year-to-date return. This surge follows strong second-quarter earnings that surpassed analyst expectations and led to increased price targets from …
Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Spencer Chief Executive Officer - Birgit Girshick Executive Vice President and Chief Financial Officer - Glenn Coleman Full Conference Call Transcript …
Every 2 Seconds, Someone in the U.S. Needs Blood as Abbott Drive Returns
Abbott (NYSE: ABT) and the Big Ten Conference have relaunched their "We Give Blood" nationwide competition to address a critical blood supply crisis in the U.S. All 18 Big Ten universities will compete to generate the most blood donations, with Abbott awarding $1 million …
Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national …
First Horizon (FHN) Stock Looks Below Fair Value While Earnings Look Fair
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. First Horizon stock has delivered a strong 120.1% return over the past three years, and the current Excess Returns intrinsic value estimate still points to a sizeable …
Are Investors Undervaluing Orix Corp Ads (IX) Right Now?
Orix Corp Ads (IX) appears to be undervalued based on several key metrics, according to Zacks. The company holds a Zacks Rank #1 (Strong Buy) and an "A" grade for Value, with its P/E, PEG, and P/S ratios all indicating it is cheaper than …
New Oriental Education & Technology Group (EDU) After Earnings Buyback And Dividend News, Does Undervalued Still Fit?
New Oriental Education & Technology Group (EDU) recently announced a mix of earnings, revenue guidance, dividend plans, and a new share repurchase program. Despite recent stock price fluctuations, the company is considered undervalued by a key valuation narrative at $70.80, supported by improved operating …
Mesa Laboratories (MLAB) Stock Jumps As Margin Gains Meet Backlog Doubts
Mesa Laboratories' stock jumped 9.5% after its Q1 2027 earnings, with investors focusing on improved profitability despite modest revenue growth. Gross margins increased, and cash generation was solid, but net income and EPS declined year-on-year. The company faces risks from backlog issues and customer …
Orion Energy Systems (NASDAQ:OESX) Rating Increased to Strong-Buy at Zacks Research
Zacks Research has upgraded Orion Energy Systems (NASDAQ:OESX) to a "strong-buy" rating from "strong sell." This upgrade contributes to a "Moderate Buy" consensus rating for the stock, with an average price target of $30.00. The company recently reported strong quarterly results, with EPS of …
HC Wainwright Issues Pessimistic Outlook for ORIC Earnings
HC Wainwright has revised down its earnings per share forecasts for Oric Pharmaceuticals (NASDAQ:ORIC) for Q3 2026 and FY2026, projecting larger losses. Despite the more pessimistic outlook, HC Wainwright maintained a "Buy" rating and a $27 price target on the stock. Oric Pharmaceuticals recently …
Abbott Laboratories $ABT Shares Sold by West Branch Capital LLC
West Branch Capital LLC significantly reduced its stake in Abbott Laboratories (NYSE:ABT) by 83.5% in the second quarter, selling 13,061 shares and retaining 2,576 shares worth $234,000. Despite this sell-off, institutional investors collectively own 75.18% of Abbott’s stock. Abbott reported strong Q2 earnings of …
Norges Bank (EDU) reports 83.0M-share, 4.84% stake in New Oriental
Norges Bank, Norway's central bank, has filed an amended Schedule 13G, disclosing a beneficial ownership of 83,017,990 shares, or 4.8429%, in New Oriental Education & Technology Group Inc. as of June 30, 2026. The filing indicates Norges Bank holds sole voting power over 81.49 …
Wasatch Advisors LP Buys 357,276 Shares of Orion Group Holdings, Inc. $ORN
Wasatch Advisors LP significantly increased its stake in Orion Group Holdings, Inc. (NYSE:ORN) during the second quarter, purchasing 357,276 additional shares to bring its total holdings to over 2 million shares, representing 4.98% of the company. Institutional investors now own 70.25% of Orion Group, …
Charles River Laboratories International, Inc. $CRL Shares Sold by Pacer Advisors Inc.
Pacer Advisors Inc. significantly reduced its stake in Charles River Laboratories International (NYSE: CRL) by 98.4% in the first quarter, selling over 151,000 shares. Despite this, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and a $255.65 average price target. The …